Home - CorMedix | Prevention of cardiac, renal and infectious diseasesTime 2022-09-24 12:12:41
Defencath™ , an investigational drug product, is a novel, antimicrobial and antifungal solution being developed for the prevention of catheter-related bloodstream infections (“CRBSIs”) in patients with end-stage renal disease receiving hemodialysis through a central venous catheter.
Defencath™, an investigational drug product, was granted FDA Fast Track status and is designated as a Qualified Infectious Disease Product.
Latest NewsSeptember 7, 2022 CorMedix Inc. to present at the H.C. Wainwright Annual Global investment conference August 11, 2022 CorMedix Inc. Reports SECOND Quarter AND SIX MONTH 2022 Financial Results and Provides Business Update
CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease
<<< Thank you for your visit >>>